// App-Quantinova.ai

2152 : Bosutinib for Previously Treated Patients with Philadelphia Chromosome-Positive Leukemia: ≥8-Year Update of a Phase 1/2 Study

Researchers

Presenter

  • Tim H Brmmendorf

Principal Investigators

  • Jorge E. Cortes

  • Yeow Tee Goh

  • Musa Yilmaz

  • Rebecca B. Klisovic

  • Simon Purcell

  • Andrea Viqueira

  • Eric Leip

  • Carlo Gambacorti-Passerini

Medical Centers

  • Uniklinik RWTH Aachen, Aachen, Germany

  • Georgia Cancer Center, Augusta University, Augusta, GA

  • Department of General Surgery, Singapore General Hospital, Singapore, Singapore

  • Department of Radiology, MD Anderson Cancer Center, Houston, TX

  • Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA

  • Pfizer Ltd, London, GBR

  • Pfizer Spain, Madrid, Spain

  • Pfizer Inc., Cambridge, MA

  • Dept. of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

Locations

  • Germany

  • United States

  • Singapore

  • Spain

  • Italy

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Bosutinib

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT00261846

  • NCT01903733

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved